Mélissa Chénard

Statistics

Publications

Citations

1.6K

H-Index

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Mélissa Chénard is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2000–2016

Publications

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Jennifer O’Neil, Yair Benita, Igor Feldman et al. · Molecular Cancer Therapeutics · 2016 · 432 citations

Medicine, Oncology, Pharmacology +13

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu et al. · Cancer Cell · 2015 · 275 citations · Full text

Medicine, Cancer Biology, Oncology +17

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

Joey L. Methot, Prasun K. Chakravarty, Mélissa Chénard et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 187 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +10

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Andrey Loboda, Michael Nebozhyn, Rich A. Klinghoffer et al. · BMC Medical Genomics · 2010 · 153 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

David J. Witter, Paul E. Harrington, Kevin J. Wilson et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 95 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

1–5 of 17